Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - NATUS MEDICAL INCa50354904ex99_1.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549


Form 8-K

Current Report


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): July 26, 2012

Natus Medical Incorporated

(Exact name of registrant as specified in its charter)

000-33001

(Commission File Number)


Delaware

 

 

 

77-0154833

(State or other jurisdiction of incorporation)

 

(I.R.S Employer Identification No.)


1501 Industrial Road
San Carlos, California 94070

(Address of principal executive offices) (Zip Code)


650-802-0400

(Registrant's telephone number, including area code)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



ITEM 2.02.      Results of Operations and Financial Condition.

On July 26, 2012, Natus Medical Incorporated (the “Company”) is issuing a press release and holding a conference call regarding its financial results for the second quarter ended June 30, 2012 and other financial information.  A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

The information in this Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 9.01.     Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.

 

Description

99.1 Press release dated July 26, 2012 describing the Company’s results for its second quarter ended June 30, 2012 and other financial information.


SIGNATURES

          Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

               NATUS MEDICAL INCORPORATED

     (Registrant)

 

 

 

By:

/s/ Steven J. Murphy

 

Steven J. Murphy

 

Vice President Finance and Chief Financial Officer

 

Dated:

July 26, 2012


Exhibit Index

Exhibit
No.

Description

 
99.1

Press release dated July 26, 2012 describing the Company’s results for its second quarter ended June 30, 2012 and other financial information.